Harmful or not: Trichostatin A treatment of embryos generated by ICSI or ROSI

Harmful or not: Trichostatin A treatment of embryos generated by ICSI or ROSI
复制标题

DOI:
10.2478/s11535-006-0023-5
复制
发表时间:
2006-09-01
影响因子:
--
通讯作者:
Wakayama, Teruhiko
Wakayama, Teruhiko
中科院分区:
其他
文献类型:
--
作者:
Kishigami, Satoshi;Ohta, Hiroshi;Wakayama, Teruhiko

文献摘要

被引文献

相似文献

曲古抑素A(TSA)是一种组蛋白去乙酰酶抑制剂,是一种已知的致畸原,在植入后阶段应用时会导致脊柱融合等畸形;在植入前阶段应用TSA也会导致发育停滞。不管这些障碍,我们已经成功地建立了一种有效的小鼠体细胞方法,其中重建的胚胎用TSA处理。为了阐明这一明显的差异,我们用50 nM的TSA处理受精后20h的受精鼠卵胞浆内单精子注射(ICSI)或圆形精子细胞注射(ROSI)产生的受精卵以及孤雌胚胎,发现TSA处理抑制了ICSI胚胎的着床前发育,但不抑制ROSI或孤雌生殖胚胎的发育。而且,尽管我们经常观察到TSA治疗后胚胎发育到足月的亚型,这两种ICSI(av.体重:1.7g比1.5g)和ROSI(1.6g比1.2g),TSA处理使ICSI的子代繁殖率从57%降低到34%,而ROSI的子代繁殖率从30%下降到36%。因此,这些数据表明,TSA治疗对胚胎发育的影响,无论是有害的还是无害的,取决于它们在当前的辅助生殖技术中的程序。(C)Versita Warsaw和Spring-Verlag柏林海德堡。版权所有。
Trichostatin A (TSA), a histone deacetylase inhibitor, is a known teratogen causing malformations such as vertebral fusions when applied during the postimplantation period; TSA also causes developmental arrest when applied during the preimplantantion period. Regardless of these hindrances, we have succeeded in the establishment of an efficient somatic method for the mouse where reconstructed embryos are treated with TSA. To elucidate this apparent discrepancy, we treated fertilized mouse embyros generated either by intracytoplasmic sperm injection (ICSI) or round spermatid injection (ROSI) with 50 nM TSA for 20 h after fertilization as well as parthenogenetic embyros and found that TSA treatment inhibited the preimplantation development of ICSI embyros but not ROSI or parthenogenetic embyros. And, although we often observed hypomorphism following TSA treatment in embyros grown to full term produced by both ICSI (av. of body weight: 1.7 g vs. 1.5 g) and ROSI (1.6 g vs. 1.2 g), TSA treatment reduced the offspring production rate for ICSI from 57% to 34% but not for ROSI from 30% to 36%. Thus, these data indicate that the effects, harmful or not, of TSA treatment on embryonic development depend on their procedure in current Assisted Reproductive Technologies.(c) Versita Warsaw and Spring-Verlag Berlin Heidelberg. All rights reserved.